Menu Search
Equities

Resverlogix Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
RFS:STU

Resverlogix Corp

Actions
  • Price (EUR)0.058
  • Today's Change0.003 / 5.45%
  • Shares traded0.00
  • 1 Year change+81.25%
  • Beta1.0719
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-9.73m
  • Incorporated2005
  • Employees18.00
  • Location
    Resverlogix Corp300-4820 Richard Rd SWCALGARY T3E 6L1CanadaCAN
  • Phone+1 (403) 254-9252
  • Fax+1 (403) 254-9252
  • Websitehttps://www.resverlogix.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.